Jafron Biomedical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 39.15%

Jafron Biomedical Co Ltd (300529) has an Asset Resilience Ratio of 39.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥2.16 Billion

≈ $316.31 Million USD Cash + Short-term Investments

Total Assets

CN¥5.52 Billion

≈ $807.93 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jafron Biomedical Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Jafron Biomedical Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Jafron Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jafron Biomedical Co Ltd (300529) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥2.16 Billion	39.15%
Total Liquid Assets	CN¥2.16 Billion	39.15%

Asset Resilience Insights

Very High Liquidity: Jafron Biomedical Co Ltd maintains exceptional liquid asset reserves at 39.15% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Jafron Biomedical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jafron Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Cochlear Ltd AU:COH	Medical Devices	9.76%
Novocure Ltd NASDAQ:NVCR	Medical Devices	43.72%
Sinocare Inc SHE:300298	Medical Devices	3.53%
L&C Bio Co. Ltd KQ:290650	Medical Devices	2.14%
Shanghai ZJ Bio-Tech Co. Ltd. A SHG:688317	Medical Devices	10.88%
Bactiguard Holding AB (publ) ST:BACTI-B	Medical Devices	8.12%
Oncosil Medical Ltd AU:OSL	Medical Devices	0.00%
Anteris Technologies Global Corp AU:AVR	Medical Devices	33.27%

Annual Asset Resilience Ratio for Jafron Biomedical Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jafron Biomedical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	CN¥61.82K ≈ $9.05K	CN¥5.41 Billion ≈ $791.50 Million	-11.02pp
2024-12-31	11.02%	CN¥593.07 Million ≈ $86.79 Million	CN¥5.38 Billion ≈ $787.77 Million	+7.90pp
2021-12-31	3.12%	CN¥150.01 Million ≈ $21.95 Million	CN¥4.81 Billion ≈ $703.87 Million	-4.57pp
2016-12-31	7.69%	CN¥100.00 Million ≈ $14.63 Million	CN¥1.30 Billion ≈ $190.21 Million	--

pp = percentage points

About Jafron Biomedical Co Ltd

SHE:300529 China Medical Devices

Market Cap

$2.21 Billion

CN¥15.09 Billion CNY

Market Cap Rank

#5769 Global

#1061 in China

Share Price

CN¥18.89

Change (1 day)

+1.56%

52-Week Range

CN¥15.04 - CN¥24.54

All Time High

CN¥96.12